Background-The aim of this study is to determine whether B 12 replacement would ameliorate cognitive and psychiatric symptoms in elderly subjects with dementia and low serum B 12 levels.
Introduction
Serum vitamin B 12 (cobalamin) testing has long been -and continues to be -recommended as part of the routine screening of patients with dementia (American Psychiatric Association, 2007) . This recommendation reflects the widespread assumption that B 12 deficiency is a reversible cause of dementia, or at least is commonly associated with cognitive impairment that may be partially correctable. However, surprisingly little research has systematically examined the cognitive and behavioral response to treatment of low serum B 12 levels in the setting of dementia. A full diagnostic work-up is frequently not undertaken until a dementing illness is well established; and when B 12 deficiency is diagnosed in a demented patient, it is usually not the only (or even primary) etiological process involved. Furthermore, B 12 deficiency is often incidentally detected during the course of a dementia of other etiology (e.g. Alzheimer's disease). In such circumstances there is little prognostic data available to guide clinicians regarding the likely response to B 12 replacement therapy.
Further diagnostic challenges are posed by patients who present with subtle B 12 deficiency (Carmel et al., 1987) or B 12 -related neuropsychiatric syndromes without anemia or macrocytosis . These diagnostic uncertainties prompted the quest for biochemical markers of tissue B 12 deficiency and the development of assays for two metabolites that accumulate if B 12 is lacking: methylmalonic acid (MMA) and homocysteine (Hcys) (Stabler et al., 1986; 1988) . The measurement of serum MMA and Hcys in combination with serum B 12 levels has enlarged the understanding of B 12 deficiency considerably beyond the classically described megaloblastic anemia and subacute combined systems disease. For example, if defined by an elevated serum concentration of MMA, then B 12 deficiency is a relatively common condition affecting at least 15% of the elderly (Pennypacker et al., 1992; Lindenbaum et al., 1994) .
Apart from case reports, few studies have reported outcome data on the cognitive and behavioral response to treatment of low serum B 12 levels in the setting of dementia. There have been particularly few placebo-controlled trials of B 12 replacement in dementia (de la Fournière et al., 1997; Hvas et al., 2004) , presumably because placebo controls have been deemed unethical by many investigators (Martin et al., 1992; Teunisse et al., 1996) . Previous prospective studies have thus largely involved open-label designs (Martin et al., 1992; Carmel et al., 1995; Cunha et al., 1995) , in some cases with comparison to neuropsychological test performance by a reference group (Teunisse et al., 1996) or matched controls (Eastley et al., 2000) with dementia and normal B 12 levels (for a review of these studies, see Discussion). However, an intermediate solution not previously reported is to use a virtual control group of patients with normal levels for blinding of outcome raters.
In the present project we examined whether B 12 replacement would ameliorate cognitive and behavioral measures in one particular population: nursing home residents with low serum B 12 levels and relatively established cases of dementia. A test group of elderly nursing home residents with dementia and low B 12 levels and a matched comparison group with normal B 12 levels were both rated on cognitive and psychiatric scales in a single-blind manner (rater blind) while the test group received standard intramuscular (IM) B 12 replacement therapy. In addition, we used assays of MMA and Hcys to measure tissue B 12 deficiency and to relate this to clinical response to B 12 replacement. This study was conducted nearly 20 years ago but has not previously been published. Given the up-to-date methodology employed, the unique protocol design, and the current interest in B-vitamins and dementia, this study provides an important extension of contemporary knowledge.
Methods

Human subjects
The study sample consisted of 28 elderly (age ≥65 years) subjects with dementia and low serum B 12 levels (<250 pg/mL) and 28 subjects with dementia and normal B 12 levels (>300 pg/mL), who resided in a nursing facility with both skilled and intermediate care units (the Jewish Home for the Elderly, Fairfield CT, U.S.A.). Subjects were enrolled between October 1988 and August 1989 (and completed the study by December 1989). B 12 levels were obtained as part of routine annual medical examination, which included medical history, physical and neurological examinations, serum chemistries (including lactate dehydrogenase, LDH), thyroid function studies, complete blood count (CBC) (including hemoglobin, hematocrit, red blood cell (RBC), erythrocyte mean corpuscular volume (MCV), white blood cell (WBC) and differential, and platelets), B 12 , folate (RBC or serum), urinalysis, electrocardiogram, and chest X-ray. All residents with B 12 levels <250 pg/mL were invited to participate as members of the test group. From residents with normal B 12 levels (>300 pg/mL), comparison subjects were selected to participate in parallel with low B 12 subjects. Normal B 12 subjects were group-matched with low B 12 subjects for age, gender, and severity of dementia -as measured by the Mini-mental State Examination (MMSE; Folstein et al., 1975) , which was also performed as part of routine annual assessment. Cutoffs of 250 pg/mL and 300 pg/mL were adopted because of previous reports that some patients with levels up to 300 pg/mL may show B 12 -responsive neuropsychiatric disorders .
Eligibility criteria for both subject groups included DSM-IIIR criteria (American Psychiatric Association, 1987) for dementia and a score of ≤ 24 on MMSE (Folstein et al., 1975) .
Subjects were excluded who were currently receiving B 12 replacement therapy; had severe sensory impairment (e.g. blindness) which precluded use of standard cognitive and psychiatric rating scales; or had a neurological disease likely to produce marked cognitive or behavioral change during the study (e.g. brain tumor). However, eligibility criteria were otherwise very liberal in order to study effects of B 12 replacement across a broad spectrum of clinical dementia in the nursing home setting. Thus subjects were included across the full severity range of dementia (MMSE=0-24), with stable neurological diseases, or receiving central nervous system (CNS) active medications. Psychotropic medication use was common in both the low B 12 (antipsychotics 7, benzodiazepines 7, antidepressants 3) and normal B 12 (antipsychotics 11, benzodiazepines 5, antidepressants 4) groups. All subjects who met eligibility criteria for low or normal B 12 groups agreed to participate and were enrolled during a 10-month period. All subjects (or their responsible next of kin) provided informed consent, and were studied under a protocol approved by the Yale Human Investigation Committee.
Subjects were initially evaluated by a geriatric psychiatry fellow (CHvD) to establish the diagnosis, classification, and characteristics of dementia (American Psychiatric Association, 1987) . This evaluation included a review of symptoms, neurological examination, interview of family members, and detailed chart review. In addition to annual medical examinations (see above), a VDRL (test for syphilis) had been performed on all subjects at the time of nursing home admission. Twenty-seven of the 56 subjects had had a previous documented head CT (computed tomography scan) or MRI (magnetic resonance imaging) performed since onset of dementia. Subjects were classified according to the probable etiology of dementia, assuming that B 12 deficiency was not exclusively causal. Classification of dementia in the low B 12 group included: primary degenerative dementia of the Alzheimer type (DAT) (American Psychiatric Association, 1987) (18), multi-infarct dementia (MID) (American Psychiatric Association, 1987) (3), DAT plus MID (patients who met some criteria for both etiologies, e.g. a progressive dementia with a recent stroke) (3), DAT plus Parkinson's disease (PD) (3), and DAT plus Herpes encephalitis (1). Classification of dementia in the normal B 12 group included: DAT (22), MID (2), DAT plus MID (2), DAT plus PD (1), and DAT plus dementia due to head trauma (1).
Procedure
All low B 12 subjects were tested for tissue deficiency with serum MMA (Stabler et al., 1986) , and serum Hcys (Stabler et al., 1988) and administered baseline cognitive and psychiatric ratings (see below). They then received replacement B 12 therapy in a van Dyck et al. standardized manner: 1,000 μg IM daily for 1 week, then 1,000 μg IM weekly for the duration of the study (16 weeks total).
All subjects (low and normal B 12 groups) were rated by a second examiner (JML, RMR, APS; geriatric psychiatrist or psychiatry resident), blind to B 12 status, at 0 weeks (prior to initiation of B 12 treatment for the low B 12 group), 8 weeks, and 16 weeks with the following scales: (1) Dementia Rating Scale (DRS, scoring range 0-144) (Mattis, 1976) which has been found to be sensitive to change in patients with moderate to severe dementia (Salmon et al., 1990) ; (2) Brief Psychiatric Rating Scale (BPRS, 16-item, scoring range 16-112) (Overall and Gorham, 1962) ; (3) Geriatric Depression Scale-abbreviated version (GDS, scoring range 0-15) (Brink et al., 1982; Sheikh and Yesavage, 1986) . Some subjects with severe dementia were considered unratable using the BPRS and/or GDS and their data were not included in the analysis of those variables.
After 8 weeks, CBC, LDH, MMA and Hcys were repeated for low B 12 subjects to measure hematologic and metabolic response to treatment.
Laboratory studies
All laboratory studies were performed by Metpath-Columbia Laboratory (Bridgeport, CT and Teterboro, NJ). Serum B 12 and RBC folate assays utilized competitive protein binding. MMA and Hcys assays employed capillary gas chromatography-mass spectrometry. Initially, they were performed (under contractual agreement with Metpath) at the laboratories of Robert H. Allen and Sally P. Stabler (University of Colorado) where they were developed before this technology was transferred to Metpath's Teterboro, NJ laboratory. Peripheral blood smears were read by a blinded technician in the laboratory of John E. Lindenbaum at the College of Physicians and Surgeons of Columbia University.
Statistical analysis
Baseline differences between low B 12 and normal B 12 groups were analyzed by two sample Student t-tests. Effects of B 12 treatment on hematologic and metabolic parameters in the low B 12 group were analyzed by paired t-tests at 0 and 8 weeks of treatment. However, the data for MMA were not normally distributed (Lilliefors test) and were analyzed instead by Wilcoxon matched-pairs test.
The primary efficacy variable in this study was change from baseline to week 16 in DRS score, and the secondary efficacy variables were change from baseline to week 16 in BPRS and GDS scores. All three variables were analyzed using the last observation carried forward (LOCF) approach. For each of these variables, a comparison between the two groups was performed using an analysis of covariance model (ANCOVA) with group as factor and baseline score as covariate. Change in DRS scores was not normally distributed (Lilliefors test) and were re-analyzed post-hoc by Mann-Whitney U test. The number of subjects who showed a significant individual cognitive improvement (defined as ≥12 points on DRS -an improvement equivalent to the average deterioration in score over one year in DAT patients (Salmon et al., 1990) ) was compared between groups by χ 2 . Correlations between variables were analyzed using Pearson's product moment correlation (r) or Spearman's rank correlation coefficient (ρ) depending on the normality of data.
All statistical analyses employed two-tailed tests of significance, using a significance level of α 0.05. All statistical analyses were performed using=SPSS (SPSS Inc., Chicago, IL) or SYSTAT (SYSTAT Inc., Evanston, IL) software.
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Results
Subject characteristics
Demographic, clinical, and baseline neuropsychological characteristics of low B 12 and normal B 12 dementia subjects are displayed in Table 1 . The two groups did not differ significantly in age, gender, education, duration of dementia, or Hachinski ischemia score (Hachinski et al., 1975) . They also did not differ in any neuropsychological measure at baseline (MMSE, DRS, GDS, or BPRS), although there was a nonsignificant trend for low B 12 subjects to have higher BPRS scores than normal B 12 subjects (t=1.80, df=46, p=0.079). Twenty-five of 28 low B 12 and 23 of 28 normal B 12 subjects were considered ratable on the BPRS. BPRS scores for these subjects were similar to those reported in other dementia samples (Gottlieb et al., 1988) . Twenty-two low B 12 and 21 normal B 12 subjects were considered ratable on the GDS. GDS scores consistent with probable depression (>5) were common in both low (10/22) and normal (6/21) B 12 subjects.
Baseline hematologic findings
Baseline hematological characteristics of low B 12 and normal B 12 subjects are also displayed in Table 1 . RBC folate levels were available for 24 low B 12 and 24 normal B 12 subjects (remaining subjects instead had serum folate levels). Low B 12 subjects also had significantly lower RBC folate levels (364±157 ng/mL) than normal B 12 subjects (524±161 ng/mL; t=3.48, df=46, p=0.001), although no folate level in either group was abnormal (RBC folate <200 μg/L or serum folate <3 μg/L). Low and normal B 12 groups showed no significant differences in LDH, WBC, RBC, hemoglobin, hematocrit, MCV, or platelets. Seventeen low B 12 subjects were anemic (hemoglobin <12.0 g/dL for females or <14.0 g/dL for males), compared to 13 normal B 12 subjects. Only two low B 12 subjects had a MCV greater than 100 fL (the same number of normal B 12 subjects with MCV greater than 100 fL), consistent with previous reports (Thompson et al., 1987; Lindenbaum et al., 1988) that MCV is frequently normal in clinically important B 12 deficiency.
Peripheral blood smears were available from 25 low B 12 and 23 normal B 12 subjects at screening. Hypersegmentation of neutrophils (1 six-lobed or >5 five-lobed granulocytes per 100 polymorphonuclear neutrophils) was noted on blinded review of smears from only 3/25 low B 12 and 5/23 normal B 12 subjects. Macroovalocytes were present in only 3/25 low B 12 and 3/23 normal B 12 subjects. Intrinsic factor antibodies were obtained in 17 low B 12 subjects and were positive in only one case. Schilling tests were not performed in any subject. Twenty-two low B 12 subjects had abnormally elevated MMA levels (>270 nmol/L), and 13 had abnormally elevated Hcys levels (>16.0 μmol/L) ( Table 2 ).
Responses to B 12 therapy
LABORATORY EFFECTS-The effect of IM B 12 replacement (after 8 weeks of treatment) on pertinent laboratory values in low B 12 subjects is displayed in Table 2 . B 12 replacement resulted in small but statistically significant increases in RBC number (t=2.26, df=27, p=0.032, paired t-test) and hemoglobin (t=2.13, p=0.043) as well as a decrease in MCV (t=2.36, p=0.025). Predicted sharp declines with treatment were seen in serum MMA (from 592±626 to 179±66 nmol/L; Z=−4.62, p <0.001, Wilcoxon matched-pairs test) and total Hcys (from 17.8±8.2 to 12.3±5.6 μmol/L; t=6.11, p<0.001). Whereas 22 low B 12 subjects had abnormally elevated MMA levels (>270 nmol/L), and 13 had abnormally elevated Hcys levels (>16.0 μmol/L) pre-treatment, only 3 MMA levels and 7 Hcys levels remained elevated after 8 weeks of B 12 replacement. Baseline MMA 0.30, n=28, p=0.18) and Hcys (r=0.07, p=0.71) levels and the degree of MMA (r=−0.30, p=0.12) and Hcys (r=−0.13, p=0.52) response with treatment were all uncorrelated with B 12 levels.
Residual elevations in MMA and Hcys post-treatment appeared to be related in part to variations in renal function, as described in previous reports (Rasmussen et al., 1990; Allen et al., 1993; Savage et al., 1994) . Post-treatment Hcys levels were significantly correlated with blood urea nitrogen (BUN) (r=0.69, n=28, P <0.001) and serum creatinine (r=0.50, p=0.006). Post-treatment MMA levels were also significantly correlated with BUN (r=0.52, p=0.005) but not serum creatinine (r=0.31, p=0.11). Mean values of renal function tests for low B 12 subjects were BUN=24±11 (range 12-57) mg/dL and serum creatinine=1.2±0.6 (range 0.7-3.8) mg/dL.
Cognitive and psychiatric effects-Outcome on cognitive and psychiatric rating scales through 16 weeks is displayed in Figures 1, 2 and 3 . Two subjects (both normal B 12 ) did not complete 16-week ratings, and their data were included in the analysis using 8-week ratings, per the LOCF analysis plan. One of these subjects died suddenly of unknown cause, and the other suffered a major stroke. Although subjects were not blinded with regard to treatment, none of the low B 12 subjects was aware of receiving B 12 replacement at the end of 16-weeks, and only one subject recalled that she had received IM injections.
On the DRS (Figure 1) low B 12 subjects improved by 4.4±17.6 points from baseline to week 16, and normal B 12 subjects declined by −2.0±9.9 points. This difference trended in favor of treated low B 12 subjects according to the planned ANCOVA (F=3.24; df=1,53; p=0.077, ANCOVA). However, change in DRS scores was not normally distributed (Lilliefors Test Statistic=0.16, df=56, p=0.002) was therefore re-analyzed post-hoc and by Mann-Whitney U test and found not to be significant (Z=−0.97, p=0.33, Mann-Whitney U test). On the BPRS (Figure 2) low B 12 subjects (n=25) improved (declined) by −1.4±6.6 points, and normal B 12 subjects (n=23) worsened (increased) by 0.5±5.6 points (F=0.12; df=1,45; p=0.73, ANCOVA). On the GDS (Figure 3) low B 12 subjects (n=22) improved by 0.1±2.8 points, and normal B 12 (n=21) subjects improved by points 0.3±2.5 (F=0.00; df=1,40; p=0.97, ANCOVA). Although baseline score was the only covariate specified in the statistical plan, none of these results was altered by the addition of age, sex, and RBC folate level to the ANCOVA models.
Post-hoc analyses were performed to relate evidence for tissue deficiency (MMA or Hcys) to cognitive response to B 12 replacement. First, since normal MMA and Hcys levels may exclude clinical deficiency in subjects with low B 12 levels, a secondary analysis was done, considering only those low B 12 subjects with an elevation (2SD) in either MMA or Hcys (n=24). Using this more stringent criterion of deficiency, the magnitude of improvement on the DRS in low B 12 subjects improved slightly (to 4.8±18.9 points), although the comparison to normal B 12 subjects was still nonsignificant (F=2.45; df=1,49; p=0.12, ANCOVA) (Z=−0.94, p=0.35, Mann-Whitney U test). Second, when the relationship between change in cognition and metabolites was examined, the magnitude of improvement on the DRS paradoxically showed an inverse correlation with the magnitude of reduction in both MMA (ρ =−0.42, n=28, p=0.025) and Hcys (ρ =−0.51, p=0.006).
The number of subjects who showed a significant cognitive improvement (≥12 points on the DRS) during the study was numerically, but not statistically, greater for treated low B 12 subjects (n=6) than comparison subjects (n=2) (χ 2 =1.31, df=1, p=0.25). Six treated low B 12 subjects who met this criterion gained 71, 38, 21, 16, 15, and 13 points on the DRS, compared to two normal B 12 subjects who gained 13 and 12 points on the DRS. The subject who gained 71 points was described at baseline as emotionally withdrawn with psychomotor retardation, although she was considered ratable on DRS. Her DRS improvement was accompanied by a drop (improvement) in BPRS score of 17 points. Similarly, the subject who gained 38 points on the DRS had a reduction (improvement) in GDS score of 6 points.
Therefore these largest DRS increases may have been related to improvement in noncognitive behavioral symptoms, whether or not these were B 12 related.
Discussion
This study examined whether B 12 replacement would ameliorate cognitive and psychiatric variables in elderly nursing home residents with dementia and low serum B 12 levels. Low B 12 subjects demonstrated tissue deficiency, as B 12 replacement was associated with robust reductions in serum metabolites (MMA and Hcys) as well as small but statistically significant changes in hematologic parameters. However, B 12 treatment failed to effect statistically significant improvements in cognitive (DRS) or psychiatric (BPRS, GDS) scores. Although a few subjects evidenced notable individual treatment responses, these were not statistically more frequent than in normal B 12 subjects.
This study possessed significant limitations associated with the use of a comparison group of untreated subjects with normal B 12 levels, rather than a randomized, placebo-controlled design. This virtual control group was successful in maintaining blinded ratings of outcome measures. And although dementia subjects themselves were not technically blinded with regard to treatment status (and no placebo injections were administered to normal B 12 subjects), this likely had negligible effect, as none of the low B 12 subjects recalled receiving B 12 replacement at end of study. The major limitation of this design likely involved the inherent differences between subjects as a function of B 12 status, despite careful demographic matching and post-hoc examination of other subject variables, which may have been associated with different outcome at 16 weeks.
The ethics of placebo controls remains a significant problem for the study of cognitive and psychiatric effects of B 12 replacement in subjects with low serum B 12 levels. Although placebo-controlled trials of B 12 and other B-vitamins are widely accepted in dementia patients without evidence of deficiency, no consensus exists regarding the ethics of placebo controls in patients with low levels. As detailed in the following section, other investigators have handled this problem by conducting open-label studies (Martin et al., 1992; Carmel et al., 1995; Cunha et al., 1995) , sometimes with comparison to historical controls (Teunisse et al., 1996; Eastley et al., 2000) without low B 12 levels, and only rarely with full placebocontrolled designs (de la Fournière et al., 1997; Hvas et al., 2004) . In elderly samples with no dementia, placebo-controlled trials of B 12 have sometimes handled the ethical dilemma by excluding subjects with any evidence of anemia or neurological symptoms (Hughes et al., 1970; Seal et al., 2002) . However, this strategy is difficult to implement in practice, since minor hematological and neurological symptoms are prevalent in the elderly, and not necessarily related to low B 12 levels. Furthermore, this practice may exclude the very subjects most likely to demonstrate behavioral improvement with treatment.
Previous treatment studies of low B 12 in dementia
Apart from case reports, remarkably few studies have reported outcome data for treatment of dementia associated with low serum B 12 levels. Martin et al. (1992) studied cognitive function before and after at least 6 months of open-label B 12 treatment in 18 older subjects with low B 12 levels (<150 pmol/L) and cognitive dysfunction. Eleven of 18 subjects improved on DRS scores, two subjects by 31 and 28 points. The only clinical characteristic found to predict improvement was short duration (<12 months) of cognitive dysfunction. Carmel et al. (1995) studied metabolic, neurologic, and electrophysiologic response to openlabel B 12 replacement in 16 patients with low B 12 levels (<190 pg/mL), including 13 with dementia. They found that B 12 improved several abnormalities but not cognitive function in the 13 patients with dementia. Cunha et al. (1995) investigated 19 patients with dementia and B 12 deficiency (<200 pg/mL) and observed that 16 of 19 patients showed persistent van Dyck et al. decline with B 12 treatment at follow-up (3-24 months). All patients who demonstrated improvement on MMSE score had mild dementia with a history of less than two years.
Two previous studies have examined effects of open-label B 12 treatment on neuropsychological function in dementia patients -with comparison to a reference group (Teunisse et al., 1996) or matched controls (Eastley et al., 2000) with dementia and normal B 12 levels. Teunisse et al. (1996) gave open-label IM B 12 replacement to 26 dementia patients with low B 12 levels (<200 pg/mL). After 6 months of treatment they found no cases of dementia reversal and no difference in cognitive change scores in comparison to a reference group of 69 patients with Alzheimer's disease. Eastley et al. studied 66 patients who presented with dementia and 22 with cognitive impairment who were seen for a second assessment after treatment. Changes in neuropsychological test scores were compared with those of patients with normal serum B 12 , matched by age and diagnosis. B 12 -treated dementia patients showed no significant improvement and no less neuropsychological deterioration than their matched group. However, cognitively impaired patients improved significantly compared to matched patients on a verbal fluency test. In these two studies, psychometricians were not blinded to the B 12 treatment status of patients.
Placebo-controlled trials of B 12 replacement in dementia associated with low serum B 12 levels are exceedingly few. In their Cochrane Review of all randomized, double-blind, placebo-controlled trials of B 12 on cognitive function, Malouf and Areosa Sastre (2003) included only three trials (de la Fournière et al., 1997; Seal et al., 2002; Hvas et al., 2004) . de la Fournière et al. (1997) studied 11 subjects with a diagnosis of Alzheimer's disease with low serum B 12 levels (<240 pg/ml). Subjects were randomly assigned to receive injections of B 12 1,000 μg or placebo daily for 5 days and then one injection monthly for 5 months. Treatment and placebo groups did not differ significantly in cognitive outcome as measured by ADAS-Cog scores. Seal et al. (2002) aimed to determine the minimum dose of oral B 12 required to maintain normal serum levels. They studied 31 geriatric inpatients (onethird of whom had dementia) with low serum B 12 levels (100-150 pmol/L) and no history of anemia or neurological disorder other than stroke. They compared treatment groups randomly assigned to receive 50 μg or 10 μg of oral B 12 or placebo daily for one month and found that only the 50 μg dose produced a significant increase in serum B 12 . No significant changes were observed in MMSE scores. Hvas et al. (2004) examined effects of B 12 treatment (1,000 μg IM weekly for 4 weeks) on cognitive function and depression in a randomized placebo-controlled study of 140 subjects with elevated serum MMA (0.40-2.00 mmol/l). At baseline 40 (29%) subjects had cognitive impairment (MMSE <25), and 18 (13%) had symptoms of depression. At 3-month follow-up, no improvement was found in cognitive or depression scores. The available randomized clinical trials of B 12 in dementia samples are thus remarkably limited, with only one small dedicated study (de la Fournière et al., 1997) and another study with a large subsample with dementia (Hvas et al., 2004) . We would concur with the conclusions of Malouf and Areosa Sastre (2003) that these trials do not provide statistically significant evidence of treatment effect for B 12 supplementation compared with placebo, on cognitive function.
Limitations of present study
In addition to the absence of a placebo-controlled design, this study had a number of additional limitations that warrant comment. First, the cutoff selected for B 12 deficiency (<250 pg/mL) was somewhat higher than in most other studies. A lower cutoff may have yielded a greater degree of tissue deficiency and more significant effects of B 12 replacement. Nonetheless, when a more restrictive definition of tissue deficiency was used -i.e. when only subjects with an elevation (2SD) in either MMA or Hcys were included -the results were still nonsignificant. Second, the follow-up period (16 weeks) may have been too brief to observe full effects of B 12 replacement on cognitive and psychiatric variables. The limited hematological response (in hemoglobin and MCV) in the treated low B 12 subjects may be due in part to the still shorter laboratory retest period (8 weeks, as compared to average RBC life span of 120 days). However, we were concerned that a longer follow-up period would result in more study non-completers and more confounding intercurrent illnesses in this fragile population. Third, the long duration of dementia in this nursing home population may have mitigated against observing cognitive and behavioral effects of B 12 replacement. Some previous investigators have reported a time dependency of cognitive recovery with B 12 replacement (Martin et al., 1992; Cunha et al., 1995) . Martin et al. observed that only patients symptomatic for less than a year showed improvement with therapy (Martin et al., 1992) , whereas Cunha et al. (Cunha et al., 1995) reported improvement only in patients with mild dementia of less than two years duration. Our low B 12 sample contained only nine subjects with mild dementia (MMSE ≥20) and only six with duration ≤2years. The six treatment responders had a mean MMSE score of 10.5 and mean duration of 3.3 years and thus did not differ markedly from the overall sample. Nonetheless, the preponderance of studies in this field would suggest that future research of cognitive and psychiatric effects of B 12 should focus on patients with mild symptoms of short duration.
Conclusion
These results suggest that B 12 replacement is unlikely to benefit cognitive or psychiatric symptoms in the vast majority of elderly dementia patients with low serum B 12 levels. However, future research is warranted for patients with mild symptoms of short duration. Outcome on the Dementia Rating Scale (DRS) for low B 12 (n=28) and normal B 12 (n=28) subjects. Displayed values represent mean±SEM (SEM used for legibility). From 0 to 16 weeks low B 12 subjects improved by 4.4±17.6 (SD) points, and normal B 12 subjects declined by −2.0±9.9 points. However, this difference was not significant (F=3.24; df=1,53; p=0.077, ANCOVA) (Z=−0.97, p=0.33, Mann-Whitney U test). Outcome on the Geriatric Depression Scale -abbreviated version (GDS) for low B 12 (n=22) and normal B 12 (n=21) subjects. Displayed values represent mean±SEM (SEM used for legibility). From 0 to 16 weeks low B 12 subjects improved by 0.1±2.8 (SD) points, and normal B 12 subjects improved by 0.3±2.5 points (F=0.00; df=1,40; p=0.97, ANCOVA). Table 1 Subject characteristics Note: LDH, lactate dehydrogenase; WBC, white blood cell count; RBC, red blood cell count; MCV, erythrocyte mean corpuscular volume. P-values are from paired t-tests for all variables except Methylmalonic Acid, which is from Wilcoxon matched-pairs test.
